Trial Profile
A Phase II Open Label, Roll Over Study of the Long Term Tolerability, Safety and Efficacy of Oral BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Acronyms TOMORROW
- Sponsors Boehringer Ingelheim
- 20 May 2020 Results (n= 1259) of post hoc, pooled subgroup analyses by TORVAN Stage has been presented at the 116th International Conference of the American Thoracic Society.
- 23 May 2018 Results of pooled analysis assessing safety from six studies (INPULSIS-1, INPULSIS-2, TOMORROW and their open-label extension) presented at the 114th International Conference of the American Thoracic Society.
- 01 Mar 2017 Status changed from active, no longer recruiting to completed.